Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-044910
Filing Date
2025-05-16
Accepted
2025-05-16 16:30:15
Documents
19
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT ea0240986-def14a_abvcbio.htm   iXBRL DEF 14A 3069346
2 GRAPHIC image_001.jpg GRAPHIC 35654
3 GRAPHIC image_002.jpg GRAPHIC 21048
  Complete submission text file 0001213900-25-044910.txt   4028183

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20241231.xsd EX-101.SCH 10389
5 XBRL DEFINITION FILE abvc-20241231_def.xml EX-101.DEF 1917
6 XBRL LABEL FILE abvc-20241231_lab.xml EX-101.LAB 35975
7 XBRL PRESENTATION FILE abvc-20241231_pre.xml EX-101.PRE 2239
21 EXTRACTED XBRL INSTANCE DOCUMENT ea0240986-def14a_abvcbio_htm.xml XML 5419
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40700 | Film No.: 25959746
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)